Introduction
============

Based on co-evolutionary processes pathogens have developed escape mechanisms to avoid rapid elimination by host-derived components of the immune system such as antimicrobial peptides and phagocytes. Especially the vector-borne parasites *Leishmania* (*L*.) *major* established efficient methods to have a lead over the host defense mechanism: they hide and replicate within host cells (Olivier et al., [@B58]). Most of the host cells for *Leishmania* parasites belong to the mononuclear phagocyte system that is divided into (i) differentiated macrophages, (ii) dendritic cells (DCs), and (iii) monocytes (Ritter et al., [@B64]; Yona and Jung, [@B103]). In addition, it is documented that neutrophils can harbor *L. major* parasites as well (Ritter et al., [@B64]). However, the number of such skin-resident host cells is limited. Given that limitation, a recruitment of additional host cells is pivotal for subsequent replication and spreading of the parasites (Ritter et al., [@B69]; Dupasquier et al., [@B19]). It appears somehow paradox that those innate defense mechanisms that are characterized by a massive inflammation process and attraction of further myeloid cells to the site of infection, give the parasites an advantage: the parasites expand within that recruited host cells.

The procedures involved in extravasation of myeloid cells from the blood stream to the site of infection are complex (Imhof and Aurrand-Lions, [@B29]) and will not be discussed in detail in this review due to space limitation. Nevertheless, it is important to mention that a broad spectrum of myeloid cells express adhesion molecules such as α~M~β~2~-integrin (also known as CD11b--CD18) and α~x~β~2~-integrin (also known as CD11c--CD18) that are involved in those homing processes (Imhof and Aurrand-Lions, [@B29]). Thus, it might be possible that a heterogeneous pool of different myeloid subsets is recruited to the inflamed tissue by similar mechanisms (Imhof and Aurrand-Lions, [@B29]; Leon and Ardavin, [@B39]). Once placed within the dermal compartment neutrophils and macrophages can release chemokines and pro-inflammatory cytokines, which in turn attract additional myeloid-derived host cells for further infection (Ritter and Korner, [@B65]; Peters et al., [@B61]).

It is commonly accepted that terminally differentiated myeloid cells fulfill controversial functions in infectious diseases such as leishmaniasis: macrophages are crucial for parasite replication and parasite elimination (after appropriate activation), DCs are bridging the innate and adaptive immune response and infected neutrophils can be taken up by macrophages resulting in a pronounced replication of parasites (Bogdan and Rollinghoff, [@B6]; Bogdan et al., [@B5]). However, those "classical" myeloid cells, denominated as "macrophage" or "DC," have been further subdivided into distinct subsets according to certain cluster of differentiation (CD)-patterns and the additional expression of additive molecules and cytokines. Based on that multi-parameter analysis it became difficult to precisely appoint distinct myeloid cell subsets (Table [1](#T1){ref-type="table"}). Furthermore, it is obvious that such *ex vivo* or *in situ* characterization of a myeloid cell, represents one distinct snapshot in their life span. Thus, it is feasible that the identified phenotypes do not obligatory represent "myeloid subsets" but rather represent a transient stage in the life of these cells -- influenced by the local environmental conditions.

###### 

**Surface marker expression of myeloid cell subsets**.

          Monocytes                                                                 Macrophages                                             Monocytic MDSCs                                                           Granulocytic MDSCs
  ------- ------------------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------------------- -------------------------------------------------------------------------
  CDllb   +++ (Leenen et al., [@B38]; Sunderkotter et al., [@B89])                  ++ (Leenen et al., [@B38]; Henderson et al., [@B26])    ++ (Youn et al., [@B105])                                                 ++ (Youn et al., [@B105])
  CDllc   − (Auffray et al., [@B1])                                                 \+ (Hume, [@B28])                                       \+ (Umemura et al., [@B94])                                               \+ (Umemura et al., [@B94])
  F4/80   \+ (Henderson et al., [@B26]; Sunderkotter et al., [@B89])                +++ (Leenen et al., [@B38]; Henderson et al., [@B26])   ++ (Movahedi et al., [@B53])                                              − (Youn et al., [@B104])
  Gr-1    \+ (Henderson et al., [@B26])                                             \+ (Henderson et al., [@B26])                           ++ (Umemura et al., [@B94]; Youn et al., [@B105])                         ++ (Umemura et al., [@B94]; Youn et al., [@B105])
  Ly6C    +++ (Leenen et al., [@B38]; Sunderkotter et al., [@B89])                  +/− (Sunderkotter et al., [@B89])                       +++ (Youn et al., [@B105])                                                \+ (Youn et al., [@B105])
  Ly6G    − (Auffray et al., [@B1])                                                 − (Auffray et al., [@B1])                               − (Youn et al., [@B105])                                                  ++ (Youn et al., [@B105])
  iNOs    +++ (Auffray et al., [@B1])                                               ++ (Fang and Vazquez-Torres, [@B21])                    +++ (Youn et al., [@B105]; Gabrilovich and Nagaraj, [@B23])               \+ (Youn et al., [@B105]; Gabrilovich and Nagaraj, [@B23])
  TNF     +++ (Auffray et al., [@B1])                                               ++ (Rappolee and Werb, [@B62])                          \+ (Umemura et al., [@B94])                                               \+ (Umemura et al., [@B94])
                                                                                                                                                                                                                      
          **pDC**                                                                   **Tip-DCs**                                             **cDCs CD4^−^ CD8α ^−^ **                                                 **cDCs CD4^−^ CD8α ^+^ **
                                                                                                                                                                                                                      
  CDllb   − (Henderson et al., [@B26]; Okada et al., [@B57])                        \+ (Serbina et al., [@B82])                             ++ (McLellan et al., [@B48]; Shortman and Liu, [@B83])                    − (McLellan et al., [@B48]; Shortman and Liu, [@B83])
  CDllc   \+ (Shortman and Liu, [@B83]; Vremec, [@B96])                             \+ (Shortman and Liu, [@B83]; Serbina et al., [@B82])   +++ (McLellan et al., [@B48]; Shortman and Liu, [@B83]; Vremec, [@B96])   +++ (McLellan et al., [@B48]; Shortman and Liu, [@B83]; Vremec, [@B96])
  F4/80   +/− (Vremec, [@B96])                                                      − (Serbina et al., [@B82])                              \+ (McLellan et al., [@B48]; Vremec, [@B96])                              − (McLellan et al., [@B48])
  Gr-1    \+ (Nakano et al., [@B56]; Shortman and Liu, [@B83])                      \+ (Serbina et al., [@B82])                             − (McLellan et al., [@B48])                                               − (McLellan et al., [@B48])
  Ly6C    \+ (Okada et al., [@B57]; Colonna et al., [@B13])                         − (Serbina et al., [@B82])                              −/+ (Segura et al., [@B79]; Davison and King, [@B15])                     −/+ (Segura et al., [@B79]; Davison and King, [@B15])
  Ly6G    − (Shortman and Liu, [@B83]; Okada et al., [@B57])                        \+ (Serbina et al., [@B82])                             − (McLellan et al., [@B48])                                               − (McLellan et al., [@B48])
  iNOs    − (Schleicher et al., [@B77])                                             ++ (Serbina et al., [@B82]; Auffray et al., [@B1])      − (Tam and Wick, [@B91])                                                  − (Tam and Wick, [@B91])
  TNF     − (Langhorne et al., [@B36])                                              ++ (Serbina et al., [@B82]; Auffray et al., [@B1])      −/+ (Tam and Wick, [@B91])                                                −/+ (Tam and Wick, [@B91])
                                                                                                                                                                                                                      
          **cDCs CD4^+^ CD8α^−^**                                                   **BMDC**                                                **dDC**                                                                   **LC**
                                                                                                                                                                                                                      
  CDllb   ++ (Shortman and Liu, [@B83]; Vremec, [@B96])                             \+ (Lutz et al., [@B45])                                \+ (Vremec, [@B96])                                                       \+ (Shortman and Liu, [@B83])
  CDllc   +++ (McLellan et al., [@B48]; Shortman and Liu, [@B83]; Vremec, [@B96])   \+ (Lutz et al., [@B45])                                \+ (Turley et al., [@B93])                                                \+ (Turley et al., [@B93])
  F4/80   \+ (McLellan et al., [@B48]; Vremec, [@B96])                              −/+ (Lutz et al., [@B45])                               −/+ (Merad et al., [@B50])                                                +/− (Merad et al., [@B50]; Romani et al., [@B75])
  Gr-1    \+ (McLellan et al., [@B48])                                              \+ (Lutz et al., [@B45])                                (?)                                                                       − (Ginhoux et al., [@B24])
  Ly6C    −/+ (Segura et al., [@B79]; Davison and King, [@B15])                     − (Lutz et al., [@B45])                                 (?)                                                                       − (Ginhoux et al., [@B24])
  Ly6G    − (McLellan et al., [@B48])                                               −/+ (Lutz et al., [@B45])                               (?)                                                                       − (Ginhoux et al., [@B24])
  iNOs    − (Tam and Wick, [@B91])                                                  \+ (Bonham et al., [@B7]; Lu et al., [@B44])            \+ (Lowes et al., [@B43])                                                 −/+ (Blank et al., [@B4]; Sugita et al., [@B88])
  TNF     −/+ (Tam and Wick, [@B91])                                                \+ (Langhorne et al., [@B36])                           \+ (Lowes et al., [@B43])                                                 \+ (Larrick et al., [@B37])

*(?, controversially discussed; MDSC, myeloid-derived suppressor cell; BMDC, bone marrow-derived dendritic cell; dDC, dermal dendritic cell; LC, Langerhans cell; cDC, conventional dendritic cell; pDC, plasmacytoid dendritic cell; iNOS, inducible nitric oxide synthase; TNF, tumor necrosis factor)*.

In the following section we will discuss myeloid cells commonly known as "TIP-DCs" and "MDSCs" in more detail.

TNF/iNOS Producing DCs: Tip-DCs
===============================

In 1957 it was postulated that lymphocytes proliferate in response to antigens that matches their receptor (Burnet, [@B11]). Steinman and Cohn identified a novel cell type -- denominated as DCs -- that was discussed to be involved in presentation of antigens and subsequent T cell proliferation in 1973 (Steinman and Cohn, [@B85]; Katsnelson, [@B31]). Today it is a paradigm that DCs play a pivotal role in bridging innate and adaptive immunity and consequently in T cell priming. However, the characterization of distinct surface markers (e.g., CD11c, CD11b, CD4, CD8), revealed the diversity of the DCs (Table [1](#T1){ref-type="table"}).

Dendritic cell differentiation can start with the stage of a common macrophage-DC progenitor (MDP) that has been described to be Lin^−^ CXCR1^+^ CD11b^−^ cKit^+^ CD135^+^ (Fogg et al., [@B22]). Those MDPs further differentiate into common DC progenitors (CDP) that in turn evolve to non-conventional plasmacytoid DCs (pDCs) and conventional DCs (cDCs; Fogg et al., [@B22]). Alternatively, DC maturation might occur from monocyte intermediate precursors (Fogg et al., [@B22]). The precursor of skin-associated DCs, such as epidermal Langerhans cells (LCs), is controversially discussed. There are data indicating that LCs and most likely dermal DCs (dDCs) are of myeloid origin with a monocytic intermediate (Palucka and Banchereau, [@B59]). However, other authors argue that LCs descent from fetal progenitor and belong to "‥*macrophages of the central nerve system*‥" (Auffray et al., [@B1]). Despite these developmental differences, most of the mentioned DC subsets renew under steady state conditions in lymphoid and non-lymphoid organs (Fogg et al., [@B22]; Liu et al., [@B42]; Waskow et al., [@B97]; Auffray et al., [@B1]).

Why is it essential to contemplate DC differentiation and progenitor options? Because infectious diseases, such as cutaneous leishmaniasis, are characterized by a massive turn over of myeloid cells -- including immature DC precursors -- at the site of infection. Thus, it is difficult to denominate a terminally differentiated DC subset correctly that might be involved in an immunological process *in vivo*. The changing view in the classification of LCs in experimental leishmaniasis represents a good example underlining the difficulties to dedicate the right function. In 1992 it was proposed that LCs are involved in inducing the local immune response against *L. major* parasites (Will et al., [@B102]). Twelve years later, based on the possibility for LC depletion, authors described a novel subset of a dermal DC (dDC) which were responsible for the induction of protective T helper (T~h~) 1 response in leishmaniasis whereas LCs were priming self-regulatory T cells (IL-10 producing type 1 regulatory T cells; T~r1~ cells) and T~regs~ (Moreno, [@B52]; Brewig et al., [@B9]; Kautz-Neu et al., [@B32]).

A novel DC subset was introduced into the field in 2004 (Serbina et al., [@B82]). Those DCs (CD11b^int^ CD11c^int^ Gr-1^+^ DEC-205^−^ CD14^−^ F4/80^−^) were shown to produce TNF and iNOS/NO during *Listeria* (*L*.) *monocytogenes* infection (Serbina et al., [@B82]). Due to the fact that the presented DCs produce high levels of co-stimulatory molecules, prime alloreactive T cells, do not adhere, and have a DC-like morphology, these TNF/iNOS producing DCs were denominated Tip-DCs (Serbina et al., [@B82]). Considering that TNF (Virna et al., [@B95]) and iNOS expression (MacMicking et al., [@B46]) are pivotal for the control of *L*. *monocytogenes*, the authors concluded that Tip-DCs are crucial for antimicrobial defense. The accumulation of Tip-DCs in the liver was also detected in mice infected with *Trypanosoma brucei*, an extracellular blood-borne parasite that can cause sleeping sickness in humans (Bosschaerts et al., [@B8]). Based on their findings, the authors concluded that TNF released by Tip-DC is responsible for severe liver injury in trypanosomiasis (Bosschaerts et al., [@B8]). Thus, the presence of Tip-DCs in inflamed tissues can be either beneficial or destructive.

To review the relevance of Tip-DCs in experimental leishmaniasis, it is important to highlight the potential precursor of those cells and the factors that are involved in Tip-DC differentiation. As indicated above, Tip-DCs can be stained with the mAb RB6-8C5 (granulocyte-differentiation antigen/Gr-1). Notably, the mAb RB6-8C5 detects the lymphocyte antigen 6 complex, locus G and C (Ly6G and Ly6C; Ritter et al., [@B64]). Thus Tip-DCs can be positive for Ly6C and/or Ly6G, which are known to be expressed on immature monocytes, DCs, and neutrophils (Table [1](#T1){ref-type="table"}; Lutz et al., [@B45]; Sunderkotter et al., [@B89]; Ritter et al., [@B64]).

In the murine infection model for *T. brucei* described by Bosschaerts et al. ([@B8]), CCR2^+^ inflammatory monocytic cells derived from CD11b and Ly6C expressing cells were discussed to represent the precursor of liver Tip-DCs. In their experimental model, the differentiation to Tip-DCs from immature DCs (CD11c^+^ but CD80/CD86/MHC-class II^low^) is independent of IFN-γ and MyD88 signaling, whereas IFN-γ stimulation is necessary for TNF and iNOS/NO production (Bosschaerts et al., [@B8]). Based on the facts mentioned above, it is obvious that TiP-DCs can derive from CCR2^+^ Ly6C^high^ (Serbina and Pamer, [@B81]) macrophage/DC progenitor (MDP) cells and have the potential to produce TNF/NO after appropriate stimulation.

In general the production of iNOS and TNF can be induced in different DC populations after appropriate stimulation (Munder et al., [@B54]). For instance, bone marrow-derived DCs (CD11c^+^, CD11b^+^, F4/80^−^) are known to produce TNF (Ritter et al., [@B67]) and iNOS (Wilkins-Rodriguez et al., [@B101]) after stimulation (Lu et al., [@B44]) and are positive for CCR2 (Jimenez et al., [@B30]). The only DC subset known so far that does not produce iNOS and TNF in parallel are pDCs (CD11b^−^, CD11c^int^, B220^+^, Ly6C^+^, Gr-1^+^, CD62L^+^, and CD45RA^+^ Colonna et al., [@B13]; Schleicher et al., [@B77]) and eventually epidermal LCs (Langerin^+^/CD103^−^; Blank et al., [@B4]). Thus, it is difficult to see the dissimilarity of TiP-DCs and other activated monocyte-derived cells (Taylor et al., [@B92]; Hume, [@B28]). In other words it cannot be excluded that TiP-DCs do not represent a distinct DC subset but rather belong to common monocyte-derived DC responding to their environment with TNF/NO production (Serbina et al., [@B82]).

Nevertheless, the molecules TNF and iNOS expressed by Tip-DCs, are substantial for the host defense against the obligatory intracellular pathogen *L. major* (Diefenbach et al., [@B17]; Wilhelm et al., [@B100]). Additionally, it was shown that Tip-DCs also release IFN-β that is known to promote healing of leishmaniasis (Mattner et al., [@B47]; Dresing et al., [@B18]; Solodova et al., [@B84]). There are very limited data published demonstrating the existence of iNOS producing DCs in experimental leishmaniasis (Leon et al., [@B40]). Furthermore, only a minor population of DCs in skin-draining lymph nodes (SDLNs; \<2%) could be assigned to the phenotype of "Tip-DCs" (De Trez et al., [@B16]).

Summarizing published reports so far, we assume the following hypothetical scenario for the role of Tip-DCs in experimental leishmaniasis. Here, we focused on the early phase (parasite replication, innate immune response) and the intermediate phase (parasite control, adaptive immune response).

Early after infection
---------------------

Skin-resident macrophages and/or neutrophils get infected with promastigote *Leishmania* parasites after intra dermal inoculation (Peters et al., [@B61]). Thereafter, macrophages release TNF and the chemokine CCL2 after engulfment of the parasites (Ritter and Moll, [@B68]; Wenzel et al., [@B99]). These inflammatory mediators are important for the subsequent recruitment of other CCR2^+^ myeloid cells such as monocytes and/or DC precursors (Leon et al., [@B40]; Ritter et al., [@B66]). Remarkably, it was shown that the expression of IFN-γ at the site of infection increases rapidly, very short after s.c. infection (Liese et al., [@B41]; Ritter et al., [@B66]). Consequently, the recruited monocytes and DC precursor are exposed to an inflammatory environment (e.g., IFN-γ, TNF, CCL2) that might be responsible for the subsequent induction of iNOS and TNF production in monocyte-derived DCs: the phenotype of a "Tip-DCs" is induced (De Trez et al., [@B16]).

The expression of iNOS results in an accumulation of NO in the surrounding of the cell. Given the fact that NO exposure to DCs induces their apoptosis and NO exposure to T cells blocks T cell IFN-γ production, NO represents a central molecule involved in suppression of the T cell response (Lu et al., [@B44]; Ren et al., [@B63]). Serbina et al. ([@B82]) reported that Tip-DCs are not essential for T cell priming in mice infected with *L. monocytogenes*. Other data show that human Tip-DCs can prime naïve T cells toward Th1 cells *in vitro* (Chong et al., [@B12]). Thus, NO-releasing Tip-DCs might play a minor role in the expansion of antigen-specific T cells in SDLNs but might be involved in polarizing naïve T cells.

In our notion, TiP-DCs are involved in controlling parasite replication at the site of infection based on the expression of the leishmanicidal molecule NO and the maintenance of TNF-induced inflammation.

Intermediate phase
------------------

The T cell response is induced in SDLNs of infected mice within 1 week after infection (Brewig et al., [@B9]). However, it is not clear whether DCs or TiP-DCs that were recruited to the site of infection, are responsible/capable for the transfer of living parasites from the side of infection into the SDLNs (Kaye and Scott, [@B33]). Possibly, TiP-DCs might remain within the dermal compartment, whereas T~h~1-driving dDCs capture already fragmentized parasite-particles for subsequent processing (Ritter and Osterloh, [@B70]; Brewig et al., [@B9]). Keeping in mind that especially mature DC (CCR7^high^, CD40^high^) show the tendency to migrate to the SDLNs (Ritter et al., [@B67], [@B66]) it is plausible that the TNF released by Tip-DCs might therefore potentiate the maturation and subsequent migration of T~h~1-driving dDCs to the SDLNs.

CD11b^+^/Gr-1^+^ Myeloid-Derived Cells: Suppressor or Effector Cells?
=====================================================================

Ongoing immune reactions against pathogens are often associated with severe tissue damage. Thus, dampening mechanisms are important to narrow that severe side effect. However, such counter-regulating procedures must be well balanced to avoid limitations in host defense and subsequent spreading of the parasites over the entire organism.

Besides the lymphocytic population of regulatory T cells (T~regs~), myeloid cells with suppressive functions were described in 1984/85 and referred as "*natural suppressor cells*" (Strober, [@B87]; Sakaguchi, [@B76]). During the last decades myeloid cells with suppressive capacities were rediscovered in the field of oncology (Gabrilovich and Nagaraj, [@B23]). Those cells -- denominated as myeloid-derived suppressor cells (MDSCs) -- represent a heterogeneous cell population that stains for CD11b and Gr-1 (Ly6G--Ly6C). Using antibodies specific for Ly6C and Ly6G, MDSCs were further dissected in granulocytic MDSCs (CD11b^+^Ly6G^+^Ly6C^low^) and monocytic MDSCs (CD11b^+^Ly6G^+^Ly6C^high^; Gabrilovich and Nagaraj, [@B23]).

This further differentiation between sub-groups is helpful. However, the markers used for the classification of MDSCs (CD11b, Ly6G, and Ly6C) are not exclusively restricted to MDSCs. Myeloid progenitor cells and immature myeloid cells such as macrophages, granulocytes, and DC subsets are known to express the surface molecules as well (Table [1](#T1){ref-type="table"}). Additionally, it is not clear whether all characteristics of tumor-associated MDSCs can be transferred to infected tissues that eventually show different cytokine expression patterns. Nevertheless, the appearance of myeloid cells showing a MDSC phenotype during inflammation processes have been described in different infection models such as *Candida albicans* (Mencacci et al., [@B49]), *Porphyromonas gingivalis* (Ezernitchi et al., [@B20]), and *L. monocytogenes* (Sunderkotter et al., [@B89]).

Those inflammatory myeloid cells might not necessarily have the adjudicated suppressive function of a "MDSC." Therefore, the potential suppressive capacity of MDSCs was analyzed in *in vitro* assays. This data revealed that NO-secretion of immature Ly6G^+^/CD11b^+^ myeloid cells can suppress the proliferation of cells isolated from the lymph node in infection models such as experimental leishmaniasis (Pereira et al., [@B60]) and trypanosomiasis (Goni et al., [@B25]). It is believed that immunosuppressive activity of MDSCs requires cell--cell contact (Gabrilovich and Nagaraj, [@B23]). Consequently, cell-surface receptors and/or released short-lived soluble mediators might induce the suppression of the target cell. Furthermore, MDSC participate in the suppression of ongoing immune reactions by the expansion of regulatory T cells (Huang et al., [@B27]; Serafini et al., [@B80]). The mechanisms of MDSC mediated suppression are summarized in Table [2](#T2){ref-type="table"}.

###### 

**Mechanisms driving MDSC suppressive activity (ROS, reactive oxygen species; iNOS, inducible nitric oxide synthase)**.

  Mechanism of T cell suppression by MDSCs                                                                                                                                                                                                                   References
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------
  Arginase-1 activity/[l]{.smallcaps}-arginine metabolism: The absence of [l]{.smallcaps}-arginine inhibits T cell proliferation based on the reduction of CD3ζ-chain expression and cell cycle regulators such as cyclin D3 and cyclin-dependent kinase 4   Bronte and Zanovello ([@B10]), Rodriguez et al. ([@B72]), Rodriguez et al. ([@B74]), Rodriguez and Ochoa ([@B73]), Cuervo et al. ([@B14])
  iNOS activity/release of NO: suppression of the T cell function by inhibition of IL-2 receptor signaling (JAK3 and STAT5 function). Activity of iNOS metabolizes [l]{.smallcaps}-arginine (see above)                                                      Bingisser et al. ([@B3]), Rivoltini et al. ([@B71]), Cuervo et al. ([@B14])
  ROS activity: suppression of T cell response due to reduced expression of the CD3ζ-chain                                                                                                                                                                   Schmielau and Finn ([@B78]), Kusmartsev et al. ([@B34]), Szuster-Ciesielska et al. ([@B90])
  Peroxynitrite: nitration of tyrosine within the TCR/CD8 complex results in unresponsive CD8^+^ T cells                                                                                                                                                     Nagaraj et al. ([@B55])
  Expansion of regulatory T cells                                                                                                                                                                                                                            Huang et al. ([@B27]), Serafini et al. ([@B80])
  Induction of T cell apoptosis                                                                                                                                                                                                                              Zhu et al. ([@B106])

Some data indicate that MDSC mediated suppression of T cells is antigen-independent (Kusmartsev et al., [@B35]; Watanabe et al., [@B98]). Based on the fact that antigen-specific interactions between antigen-presenting cells and antigen-specific T cells prolong the antigen-specific cell--cell contact, it is most likely that MDSC-derived suppressive factors are more efficient on closed by antigen-specific T cells than on the surrounding antigen-independent T cells (Stoll et al., [@B86]; Miller et al., [@B51]; Nagaraj et al., [@B55]). However, this important aspect needs to be further investigated in the future.

Besides the *in vitro* studies, the inhibitory function and relevance of MDSCs *in vivo* is not well documented so far. Based on the data generated in experimental leishmaniasis it further remains unclear, which phase and tissue MDSCs might interfere with T cell activation *in vivo*. It is conceivable that MDSCs are involved in the elimination of the parasites and the suppression of T cell proliferation as well. Summarizing published reports so far, we assume the following hypothetical scenario for the role of MDSCs experimental leishmaniasis.

To avoid too many speculations we focused on the potential role of MDSCs in the early phase (parasite replication, innate immune response) and the intermediate phase (parasite control, adaptive immune response).

Initial phase
-------------

CD11b^+^ Ly6C^med-high^ monocytes (Sunderkotter et al., [@B89]) share homing receptors crucial for the extravasation from the blood to the infected tissue. Thus it is most likely that a pool of MDSCs cells is recruited to the site of infection. In this area immature myeloid cells get in contact with cytokines (IL-1, IL-6, CCL2, IL-10, IL-12, IL-13, IL-4, IFN-γ, TGF-β) that drive MDSC differentiation (for further reading; Gabrilovich and Nagaraj, [@B23]). Of note, IFN-γ and CCL2 are detectable shortly after infection or after phagocyte--parasite interactions (Ritter and Moll, [@B68]; Schleicher et al., [@B77]). Thus, immature CD11b^+^ Ly6C^med-high^ myeloid cells can become MDSCs as a response to their inflammatory environment. They start to produce leishmanicidal molecules such as NO and oxygen metabolites and become important effector cells involved in skin-associated host defense. At that time cells of the innate immune system are dominating the inflammatory response at the site of infection. The adaptive T~h~1 cell mediated immune response is initiated within SDLNs but is not established at the site of infection yet.

Intermediate phase
------------------

Shortly after infection *Leishmania*-specific T~h~1 cells expand within the SDLNs and accumulate at the site of infection (Brewig et al., [@B9]). Thus two different types of T cell suppression might be possible: (i) inhibition of T cell proliferation and (ii) inhibition of T cell effector functions.

Due to the fact that MDSCs show an enhanced [l]{.smallcaps}-arginine metabolism (e.g., increased arginase-1 activity) it might be possible that [l]{.smallcaps}-arginine consuming MDSCs are responsible for a local [l]{.smallcaps}-arginine deficiency. Given the fact that [l]{.smallcaps}-arginine is necessary for cell proliferation it is therefore most likely that T cell proliferation within SDLNs is reduced based on [l]{.smallcaps}-arginine limitation. Furthermore, it is possible that NO that is released by MDSCs directly inhibits the IL-2 receptor signaling and subsequently the proliferation of T cells (Bingisser et al., [@B3]). Therefore, MDSCs might be involved in the inhibition of T cell proliferation in SDLNs.

The situation at the site of infection is quite different. Already activated effector T cells migrate to the skin and the mechanism how MDSC could suppress these activated effector cell function is still not fully understood. However, it is possible that NO can inhibit the release of Th1 cytokines by T cells (Bauer et al., [@B2]) which might be mediated by reduced [l]{.smallcaps}-arginine availability in the presence of MDSCs (Cuervo et al., [@B14]). Alternatively, the induction of apoptosis of effector T cells would be an elegant way to suppress the ongoing T cell response.

Both MDSC mediated mechanisms such as controlling T cell proliferation and activity are hypothetical. However, it might represent a smart move to dampen the host-derived immune response that in turn gives some of the parasites the chance to survive within mammalians.

Summary
=======

We aimed to highlight the potential role of TiP-DCs and MDSCs in infectious diseases such as leishmaniasis. Assuredly, pathogens such as *Leishmania* parasites interact with cells from the myeloid system. However, based on the overlapping phenotypes of myeloid cells, it becomes difficult to denominate those cell types precisely. In our point of view it cannot be excluded that the novel subsets of "Tip-DCs" and "MDSCs" might not be classical "subsets" but rather represent myeloid cells in a transient maturation stage expressing different genes, in response to environment.

However, those NO-releasing myeloid cells can fulfill distinct functions in the host defense against *Leishmania* parasites: they might be involved in either controlling the parasite spreading at the site of infection or dampening ongoing T cell responses. Whether parasites can influence the differentiation of immature myeloid cells to subsequent suppression of the adaptive immune response needs to be further investigated. Additional studies are therefore necessary to learn more about the factors regulating that fascinating plasticity and the subsequent biological relevance of phagocytic cell subsets after pathogen interaction.
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